Interleukin-6 receptor antagonists in critically ill patients with Covid-19
<p><strong>Background</strong></p> The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. <p><strong>Methods</strong></p> We evaluated tocilizumab and sarilumab in an ongoing...
| Main Authors: | , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
Massachusetts Medical Society
2021
|